NanoViricides Completes Number of Financing Activities

The Company has successfully raised more than $4.3M. This raise involved issuance
of restricted shares and warrant conversions in private placements to certain
accredited investors. The Company is filing a Form 8-K disclosure with the SEC
summarizing these activities on October 5, 2009.

“With sufficient working capital to last us through December 31, 2010,”
said Eugene Seymour, MD, MPH, CEO of the Company, “we are now ready to
engage full steam with our high priority drug development activities.”

NanoViricides, Inc. is a development stage company that is creating special
purpose nanomaterials for viral therapy. The Company's novel nanoviricide™
class of drug candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs against a number
of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza,
HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes
keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.